



Committed to helping patients get access to VYXEOS



Supports healthcare providers and office staff with:

BENEFITS INVESTIGATION^a

- Helps you and your patients understand insurance coverage for VYXEOS® (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg
- · Identifies applicable copay and other out-of-pocket costs

PRIOR AUTHORIZATION SUPPORT^a

- Provides you with information on the prior authorization process
- Offers prompt and regular follow-ups on outcomes and next steps

APPEALS SUPPORT^a

 Provides support on the appeals process following a denied prior authorization, precertification, and/or claim

REIMBURSEMENT SUPPORT^a

- Answers your billing, coding, and other reimbursement guestions
- Connects you with your assigned Access and Reimbursement Manager for additional reimbursement-related questions

REFERRALS TO OTHER FINANCIAL ASSISTANCE OPTIONS

 JazzCares can also refer patients to third-party organizations that may be able to offer financial assistance for the cost of medication

Offers financial assistance or free drug programs for eligible patients:



SAVINGS CARD^a

 Eligible, commercially insured patients can pay as little as \$10 for their VYXEOS medication, subject to an annual maximum (restrictions apply)



PATIENT ASSISTANCE PROGRAM: FREE DRUG PROGRAM^b

 Uninsured or underinsured patients who meet certain financial criteria may be eligible to receive VYXEOS at no cost

ENROLL ONLINE TODAY!

Visit <u>www.jazzcares.com/hcp/vyxeos</u> or call **1-833-533-JAZZ** (**5299**), Monday-Friday, 8 AM - 8 PM ET For personal support and expertise, visit www.jazzcares.com/contact-arm/ to contact your Jazz Access and Reimbursement Manager

^aInsurance coverage and plans may vary. JazzCares provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified healthcare professional.

VYXEOS is a trademark of Jazz Pharmaceuticals. Inc.



^bSubject to financial and residency eligibility criteria.